What Is Retatrutide Used For in Research?

Retatrutide originates from Eli Lilly's incretin research programme and is structurally distinct from earlier GLP-1-class compounds because it adds glucagon receptor agonism on top of the GLP-1 and GIP activity found in dual agonists like tirzepatide. That third receptor is the key research differentiator: glucagon signaling contributes an energy-expenditure component that single- and dual-agonist compounds don't have.

The compound's Phase 2 data, published in the New England Journal of Medicine in 2023 (Jastreboff et al.), reported mean body-weight reduction of roughly 24% from baseline at 48 weeks in the highest studied dose group — a figure that made Retatrutide one of the most-requested peptides in metabolic and obesity science literature. Published research has also documented reductions in hepatic steatosis (fatty liver) and improvements in glycemic markers in trial populations.

Retatrutide has not completed Phase 3 trials or received regulatory approval anywhere, including the UAE. It remains an investigational compound, and REVIVE LAB UAE sells it exclusively as a research reference material with lot-specific Certificate of Analysis — not for human or veterinary administration.